Literature DB >> 17074279

Neurocysticercosis: current knowledge and advances.

Wayne X Shandera1, Joseph S Kass.   

Abstract

Neurocysticercosis is the most common cause of acquired seizures worldwide. Most cases of this larval stage infection of the pork tapeworm Taenia solium occur in the developing world, although increasing numbers of cases are being recognized in the United States, particularly among Hispanic immigrants. The ability of the pathogen to persist for years within the host is the subject of immunologic and biochemical investigation. The major presenting symptom is seizures, although symptoms of obstructive hydrocephalus occur if cysts are located near the ventricles or in the subarachnoid spaces. Diagnosis is dependent on clinical, radiologic, and serologic data. Therapy with antiparasitic agents, especially albendazole, is effective in large burden disease or disease within sensitive neuraxis sites (the ventricles, the subarachnoid spaces). When patients with radiologically enhancing disease are given cysticidal therapy, there appears to be a reduction in seizure recurrences. Surgery is indicated for disease in selected anatomic sites. Long-term prevention requires attention to pork husbandry and general sanitation, including the potential use of mass human chemotherapy and porcine vaccination.

Entities:  

Mesh:

Year:  2006        PMID: 17074279     DOI: 10.1007/s11910-006-0046-3

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  35 in total

1.  Vaccination of pigs to control human neurocysticercosis.

Authors:  Armando E Gonzalez; Charles G Gauci; Dylan Barber; Robert H Gilman; Victor C W Tsang; Hector H Garcia; Manuela Verastegui; Marshall W Lightowlers
Journal:  Am J Trop Med Hyg       Date:  2005-06       Impact factor: 2.345

Review 2.  New concepts in the diagnosis and management of neurocysticercosis (Taenia solium).

Authors:  Hector H Garcia; Oscar H Del Brutto; Theodore E Nash; A Clinton White; Victor C W Tsang; Robert H Gilman
Journal:  Am J Trop Med Hyg       Date:  2005-01       Impact factor: 2.345

3.  Brain granulomas in neurocysticercosis patients are associated with a Th1 and Th2 profile.

Authors:  B I Restrepo; J I Alvarez; J A Castaño; L F Arias; M Restrepo; J Trujillo; C H Colegial; J M Teale
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

4.  Cellular immune responses in human neurocysticercosis.

Authors:  J S Grewal; S Kaur; G Bhatti; I M Sawhney; N K Ganguly; R C Mahajan; N Malla
Journal:  Parasitol Res       Date:  2000-06       Impact factor: 2.289

5.  Bruns syndrome caused by intraventricular neurocysticercosis treated using flexible endoscopy.

Authors:  Jaime Torres-Corzo; Roberto Rodriguez-della Vecchia; Leonardo Rangel-Castilla
Journal:  J Neurosurg       Date:  2006-05       Impact factor: 5.115

6.  Is dementia reversible in patients with neurocysticercosis?

Authors:  J Ramirez-Bermudez; J Higuera; A L Sosa; E Lopez-Meza; M Lopez-Gomez; T Corona
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08       Impact factor: 10.154

Review 7.  Management of neurocysticercosis.

Authors:  Terrence Riley; A C White
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

8.  Short report: limited and short-lasting humoral response in Taenia solium: seropositive households compared with patients with neurocysticercosis.

Authors:  Antonio Meza-Lucas; Laura Carmona-Miranda; Roberto C García-Jerónimo; Alejandra Torrero-Miranda; Germán González-Hidalgo; Guillermo López-Castellanos; Dolores Correa
Journal:  Am J Trop Med Hyg       Date:  2003-08       Impact factor: 2.345

9.  Sequential expression of the neuropeptides substance P and somatostatin in granulomas associated with murine cysticercosis.

Authors:  Prema Robinson; A Clinton White; Dorothy E Lewis; John Thornby; Elliott David; Joel Weinstock
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

Review 10.  Current consensus guidelines for treatment of neurocysticercosis.

Authors:  Hector H García; Carlton A W Evans; Theodore E Nash; Osvaldo M Takayanagui; A Clinton White; David Botero; Vedantam Rajshekhar; Victor C W Tsang; Peter M Schantz; James C Allan; Ana Flisser; Dolores Correa; Elsa Sarti; Jon S Friedland; S Manuel Martinez; Armando E Gonzalez; Robert H Gilman; Oscar H Del Brutto
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

View more
  5 in total

1.  Intraventricular and subarachnoid basal cisterns neurocysticercosis: a comparative study between traditional treatment versus neuroendoscopic surgery.

Authors:  Jefferson V Proaño; Jaime Torres-Corzo; Roberto Rodríguez-Della Vecchia; Gabriel Guizar-Sahagun; Leonardo Rangel-Castilla
Journal:  Childs Nerv Syst       Date:  2009-06-26       Impact factor: 1.475

2.  A 37-year-old man with a painless growing mass of the thorax.

Authors:  Boris Michael Holzapfel; Christoph Schaeffeler; Ingo Jörg Banke; Simone Waldt
Journal:  Clin Orthop Relat Res       Date:  2009-08-28       Impact factor: 4.176

Review 3.  Clinical manifestations associated with neurocysticercosis: a systematic review.

Authors:  Hélène Carabin; Patrick Cyaga Ndimubanzi; Christine M Budke; Hai Nguyen; Yingjun Qian; Linda Demetry Cowan; Julie Ann Stoner; Elizabeth Rainwater; Mary Dickey
Journal:  PLoS Negl Trop Dis       Date:  2011-05-24

4.  Substance P causes seizures in neurocysticercosis.

Authors:  Prema Robinson; Armandina Garza; Joel Weinstock; Jose A Serpa; Jerry Clay Goodman; Kristian T Eckols; Bahrom Firozgary; David J Tweardy
Journal:  PLoS Pathog       Date:  2012-02-09       Impact factor: 6.823

5.  Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials.

Authors:  Dimitrios K Matthaiou; Georgios Panos; Eleni S Adamidi; Matthew E Falagas
Journal:  PLoS Negl Trop Dis       Date:  2008-03-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.